Journal of

Geriatric Medicine and GerontologyISSN: 2469-5858

Archive

 Open Access DOI:10.23937/2469-5858/1510024

Loss of Organic Reserve as a Detector of Frailty in Elderly Cancer Patients Treated with Chemotherapy

Maria-José Molina-Garrido, Carmen Guillén-Ponce and Alfonso Muriel

Article Type: Protocol Study | First Published: March 09, 2017

This study aims to identify the presence of frailty in elderly cancer patients by analysing their functional reserve. In order to do so, a prospective study of oncological patients over the age of 70 years, assessed on an outpatient basis at the Hospital Virgen de la Luz of Cuenca has been conducted, and data regarding functional reserve at various levels in the body have been collected....

 Open Access DOI:10.23937/2469-5858/1510023

Help-Seeking in Older Adults with Subjective Memory Complaints

Pakzad S, Bourque P, Tahir L, Bhalla D, French C, Savoie V and Sepehry AA

Article Type: Research Article | First Published: March 03, 2017

Evidence shows that subjective memory complaints (SMCs) could represent an important therapeutic period for people at risk for sustaining future cognitive decline, but current knowledge on the behaviour profile of the SMCs is scarce. Thus, to better understand the SMCs' help-seeking behaviour from health care professionals, a cross-sectional study using a correlational and comparative model was implemented....

 Open Access DOI:10.23937/2469-5858/1510022

Diagnosis of Dementia-Circadian Dependency?

Wolfgang Trapp, Robert Meyrer, Goran Hajak and Stefan Lautenbacher

Article Type: Short Communication | First Published: February 16, 2017

Little is known whether tests used for the diagnosis of dementia syndromes are sensitive to time of day effects. In a sample of 145 participants, no such effect (test administration either in the morning from 9.30 to 11.30 a.m. or in the afternoon from 2.30 to 4.30 p.m.) could be found for most subtests of a neurocognitive test battery (CERAD-Plus) used for the detection of dementia syndromes....

 Open Access DOI:10.23937/2469-5858/1510021

Phase II Clinical Trial of Nicotinamide for the Treatment of Mild to Moderate Alzheimer's Disease

Michael J Phelan, Ruth A Mulnard, Daniel L Gillen and Steven S Schreiber

Article Type: Research Article | First Published: February 14, 2017

Disease-modifying treatments for Alzheimer's disease (AD) are currently unavailable and are the focus of an intensive research effort. We found vitamin B3, nicotinamide (NA), to significantly reduce pathology and improve behavior in AD transgenic mice. These results led us to conduct a double-blind, placebo-controlled randomized clinical trial of NA in mild to moderate AD....

Volume 3
Issue 1